KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.

Tsetsegsaikhan Batmunkh, Eleanor F G Neal, Otgonjargal Amraa, Nadia Mazarakis, Bolor Altangerel, Naranbaatar Avaa, Lkhagvagaram Batbayar, Khishigjargal Batsukh, Kathryn Bright, Tsogjargal Burentogtokh, Lien Anh Ha Do, Gantuya Dorj, John D Hart, Otgonbold Jamiyandorj, Khulan Javkhlantugs, Sarantsetseg Jigjidsuren, Frances Justice, Shuo Li, Khaliunaa Mashbaatar, Kerryn A Moore, Narantuya Namjil, Cattram Duong Nguyen, Batbayar Ochirbat, Unursaikhan Surenjav, Helen Thomson, Bilegtsaikhan Tsolmon, Paul V Licciardi, Claire von Mollendorf, Kim Mulholland

Vaccine 66 127840

PMID41072276
PMCID-
DOI10.1016/j.vaccine.2025.127840
发表日期2025-10-10
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia. METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented. CLINICALTRIALS: gov Identifier: NCT05265065. RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported. CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。